ClinicalTrials.gg
CompletedNCT04382586Updated Oct 26, 2024Results posted

Covid-19 Infection and Pulmonary Distress Treatment With Zanubrutinib in Hospitalized Participants

A Phase 2 interventional study of Zanubrutinib and Supportive Care in COVID-19 Pulmonary Complications and COVID-19, sponsored by BeiGene. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by BeiGene · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
63
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,859 studies in COVID-19 with a site in United States — 120 open to participants now, 210 under way, 16 of them phase 3. COVID-19 · United States.

Enrollment
737th of 1,321
63 · median 91
Started
2020
with 817 others
Phase 2
349 of 1,859
14 open now
Registered
299th of 1,859
by date

Among the 1,859 studies in COVID-19 with a site in United States, this one is the 737th largest by enrollment of the 1,321 interventional ones that give a count, is one of 818 that started in 2020, is one of 349 in phase 2, and was the 299th registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

120 of the 1,859 studies in COVID-19 with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,859 studies in COVID-19 with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this study was to evaluate if the addition of zanubrutinib to supportive care increases the respiratory failure-free survival rate at Day 28 in participants hospitalized for Corona Virus Disease 2019 (COVID-19) and pulmonary distress not receiving mechanical ventilation.

03

Conditions studied

  • COVID-19 Pulmonary Complications
  • COVID-19

Browse trials for

Keywords

  • Corona Virus
  • COVID-19
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Hospitalization for COVID-19 infection
  2. Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV)-2 infection confirmed by polymerase chain reaction (PCR)
  3. Participant requires supplemental oxygen for pulmonary distress related to COVID-19 infection, and has been on supplemental oxygen for no more than 96 hours from time of screening

Key Exclusion Criteria:

  1. Malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, symptomatic inflammatory bowel disease or ulcerative colitis, or partial or complete bowel obstruction
  2. On a Bruton's tyrosine kinase (BTK) inhibitor
  3. Planned or concurrent use of a host modifiers/immune-based therapies or anti-CD20 monoclonal antibody treatment
  4. Participants with prior of current hematologic or solid tumor malignancy with treatment within 6 months prior to study entry

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
63 participants (actual)

Study arms

  • Experimental
    Zanubrutinib + Supportive Care

    Participants received zanubrutinib plus supportive care

    Drug: Zanubrutinib · Drug: Supportive Care

  • Active comparator
    Placebo + Supportive Care

    Participants received placebo plus supportive care alone

    Drug: Supportive Care · Drug: Placebo

Interventions

  • 320 mg (4 x 80 mg) capsules administered orally once daily

    Also known as: BGB-3111, Brukinsa

  • DrugSupportive Care

    Supportive care treatment was selected and administered as deemed appropriate by the study investigator

  • DrugPlacebo

    Placebo to match zanubrutinib

06

What researchers measure

Primary outcomes

  1. Number of Participants With Respiratory Failure-free Survival

    Number of participants with respiratory failure-free survival, defined as not having died or gone into respiratory failure on or before Day 28

    Time frame: Up to Day 28

  2. Time to Breathing Room Air

    Time to return to breathing room air is defined as the time from randomization date to the earliest time where the participant is stable on room air without supplemental oxygen. Total follow-up time in days is the total time of all participants from the randomization date to the first event date or Day 28 if there is no event. The rate was calculated as total number of events in which a participant returned to breathing room air on or before Day 28 divided by the total follow-up time in days.

    Time frame: Up to 7 months

Secondary outcomes

  1. Number of Participants Experiencing Respiratory Failure or Death

    Number of participants experiencing respiratory failure or death on or before Day 28

    Time frame: Up to Day 28

  2. Number of Participants With All-cause Mortality

    Number of participants with all-cause mortality on or before Day 28

    Time frame: Up to Day 28

  3. Number of Participants Discharged Alive

    Number of participants discharged alive on or before Day 28

    Time frame: Up to Day 28

  4. Number of Participants Discharged Alive From the ICU

    Number of participants discharged alive from the intensive care unit (ICU) on or before Day 28

    Time frame: Up to Day 28

  5. Number of Participants With Improvement in the World Health Organization (WHO) 8-point Ordinal Scale

    Number of participants with improvement in WHO 8-point-scale, in which improvement was considered a score that changed from ≥4 at baseline to ≤ 3 at Day 28 as assessed by the investigator. Scoring ranges from 0 = uninfected with no clinical or virologic evidence of disease to 8 = dead.

    Time frame: Up to Day 28

  6. Duration of Mechanical Ventilation

    Number of days on mechanical ventilation on or before Day 28

    Time frame: Up to Day 28

  7. Duration of Hospitalization

    Number of days hospitalized on or before Day 28

    Time frame: Up to Day 28

  8. PaO2:FiO2 Ratio

    Partial pressure of oxygen (PaO2):fraction of inspired oxygen (FiO2) ratio

    Time frame: Baseline, Day 7, Day 14, Day 21 and Day 28

  9. Number of Participants With Adverse Events

    Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), treatment-related adverse events (AEs), and TEAEs grade 3 or higher, including laboratory findings

    Time frame: Up to 7 months

07

Results

Posted Mar 2, 2022

Participant flow

A total of 63 participants were randomized to receive zanubrutinib or placebo; four were randomized to the placebo group, but did not receive placebo treatment due to death (1 participant) and investigator decision (3 participants).

Participant flow — Overall Study
MilestoneZanubrutinib + Supportive CarePlacebo + Supportive Care
Started3033
Completed1317
Not completed1716
Withdrew: Death34
Withdrew: Lost to follow-up118
Withdrew: Withdrawal by subject31
Withdrew: Physician decision03

Outcome measures

PrimaryNumber of Participants With Respiratory Failure-free Survival

Number of participants with respiratory failure-free survival, defined as not having died or gone into respiratory failure on or before Day 28

Time frame:
Up to Day 28
Reported as:
Count of participants · Participants
Number of Participants With Respiratory Failure-free Survival
ParticipantsZanubrutinib + Supportive CarePlacebo + Supportive Care
Number of Participants With Respiratory Failure-free Survival2728
Statistical analysis
  • Zanubrutinib + Supportive Care vs Placebo + Supportive Care · Unstratified 1-sided Fisher's exact test · p = 0.4099 · Odds ratio (or): 1.61 · 95% CI 0.349 to 7.391
PrimaryTime to Breathing Room Air

Time to return to breathing room air is defined as the time from randomization date to the earliest time where the participant is stable on room air without supplemental oxygen. Total follow-up time in days is the total time of all participants from the randomization date to the first event date or Day 28 if there is no event. The rate was calculated as total number of events in which a participant returned to breathing room air on or before Day 28 divided by the total follow-up time in days.

Time frame:
Up to 7 months
Reported as:
Number · Events / total follow-up in days
Time to Breathing Room Air
Events / total follow-up in daysZanubrutinib + Supportive CarePlacebo + Supportive Care
Time to Breathing Room Air0.0600.061
Statistical analysis
  • Zanubrutinib + Supportive Care vs Placebo + Supportive Care · Log Rank · p = 0.7619 · Hazard ratio (hr): 0.918 · 95% CI 0.511 to 1.648
SecondaryNumber of Participants Experiencing Respiratory Failure or Death

Number of participants experiencing respiratory failure or death on or before Day 28

Time frame:
Up to Day 28
Reported as:
Count of participants · Participants
Number of Participants Experiencing Respiratory Failure or Death
ParticipantsZanubrutinib + Supportive CarePlacebo + Supportive Care
Number of Participants Experiencing Respiratory Failure or Death35
SecondaryNumber of Participants With All-cause Mortality

Number of participants with all-cause mortality on or before Day 28

Time frame:
Up to Day 28
Reported as:
Count of participants · Participants
Number of Participants With All-cause Mortality
ParticipantsZanubrutinib + Supportive CarePlacebo + Supportive Care
Number of Participants With All-cause Mortality24
SecondaryNumber of Participants Discharged Alive

Number of participants discharged alive on or before Day 28

Time frame:
Up to Day 28
Reported as:
Count of participants · Participants
Number of Participants Discharged Alive
ParticipantsZanubrutinib + Supportive CarePlacebo + Supportive Care
Number of Participants Discharged Alive2628
SecondaryNumber of Participants Discharged Alive From the ICU

Number of participants discharged alive from the intensive care unit (ICU) on or before Day 28

Time frame:
Up to Day 28
Reported as:
Count of participants · Participants
Number of Participants Discharged Alive From the ICU
ParticipantsZanubrutinib + Supportive CarePlacebo + Supportive Care
Number of Participants Discharged Alive From the ICU32
SecondaryNumber of Participants With Improvement in the World Health Organization (WHO) 8-point Ordinal Scale

Number of participants with improvement in WHO 8-point-scale, in which improvement was considered a score that changed from ≥4 at baseline to ≤ 3 at Day 28 as assessed by the investigator. Scoring ranges from 0 = uninfected with no clinical or virologic evidence of disease to 8 = dead.

Time frame:
Up to Day 28
Reported as:
Count of participants · Participants
Number of Participants With Improvement in the World Health Organization (WHO) 8-point Ordinal Scale
ParticipantsZanubrutinib + Supportive CarePlacebo + Supportive Care
Number of Participants With Improvement in the World Health Organization (WHO) 8-point Ordinal Scale2225
SecondaryDuration of Mechanical Ventilation

Number of days on mechanical ventilation on or before Day 28

Time frame:
Up to Day 28
Reported as:
Median · Days
Duration of Mechanical Ventilation
DaysZanubrutinib + Supportive CarePlacebo + Supportive Care
Duration of Mechanical Ventilation4.0 (3 to 24)13.5 (3 to 26)
SecondaryDuration of Hospitalization

Number of days hospitalized on or before Day 28

Time frame:
Up to Day 28
Reported as:
Median · Days
Duration of Hospitalization
DaysZanubrutinib + Supportive CarePlacebo + Supportive Care
Duration of Hospitalization6.5 (3 to 28)5.0 (1 to 28)
SecondaryPaO2:FiO2 Ratio

Partial pressure of oxygen (PaO2):fraction of inspired oxygen (FiO2) ratio

Time frame:
Baseline, Day 7, Day 14, Day 21 and Day 28
Reported as:
Median · mmHg
PaO2:FiO2 Ratio
mmHgZanubrutinib + Supportive CarePlacebo + Supportive Care
Baseline—53.0 (53.0 to 53.0)
Day 782.00 (75.00 to 89.00)54.00 (52.80 to 84.30)
Day 1432.00 (32.00 to 32.00)90.60 (90.60 to 90.60)
Day 21—52.10 (52.10 to 52.10)
SecondaryNumber of Participants With Adverse Events

Number of participants with treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), treatment-related adverse events (AEs), and TEAEs grade 3 or higher, including laboratory findings

Time frame:
Up to 7 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events
ParticipantsZanubrutinib + Supportive CarePlacebo + Supportive Care
At least one TEAE1920
Grade 3 or higher66
Serious adverse event47
Treatment-related TEAE21

Adverse events

Collected over Up to 7 months. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Zanubrutinib + Supportive Care3/30 (10%)4/30 (13.3%)19/30 (63.3%)
Placebo + Supportive Care4/33 (12.1%)7/29 (24.1%)20/29 (69%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventZanubrutinib + Supportive CarePlacebo + Supportive Care
HypoxiaRespiratory, thoracic and mediastinal disorders1/302/29
Respiratory failureRespiratory, thoracic and mediastinal disorders2/302/29
AnaemiaBlood and lymphatic system disorders0/301/29
Right ventricular failureCardiac disorders0/301/29
Ischaemic strokeNervous system disorders0/301/29
Acute kidney injuryRenal and urinary disorders1/301/29
DyspnoeaRespiratory, thoracic and mediastinal disorders0/301/29
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/301/29
Respiratory distressRespiratory, thoracic and mediastinal disorders0/301/29
COVID-19 pneumoniaInfections and infestations1/300/29
Most frequent other events
Showing 10 of 68
Most frequent other events
EventZanubrutinib + Supportive CarePlacebo + Supportive Care
BradycardiaCardiac disorders5/300/29
HypomagnesaemiaMetabolism and nutrition disorders0/303/29
HeadacheNervous system disorders1/303/29
HypokalaemiaMetabolism and nutrition disorders3/301/29
ConstipationGastrointestinal disorders2/302/29
HypoalbuminaemiaMetabolism and nutrition disorders1/302/29
Pain in extremityMusculoskeletal and connective tissue disorders0/302/29
HypoxiaRespiratory, thoracic and mediastinal disorders0/302/29
DiarrhoeaGastrointestinal disorders2/301/29
NauseaGastrointestinal disorders2/300/29

Baseline characteristics

The Intent-to-Treat (ITT) Analysis Set includes all randomized participants

Age, Continuous
Age, Continuous(Years)Zanubrutinib + Supportive CarePlacebo + Supportive CareTotal
Mean56.0 ± 12.5156.0 ± 13.3056.0 ± 12.83
Sex: Female, Male
Sex: Female, Male(Participants)Zanubrutinib + Supportive CarePlacebo + Supportive CareTotal
Female161632
Male141731
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Zanubrutinib + Supportive CarePlacebo + Supportive CareTotal
Hispanic or Latino13619
Not Hispanic or Latino162642
Unknown or Not Reported112
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Zanubrutinib + Supportive CarePlacebo + Supportive CareTotal
Asian224
Black or African American358
White192544
Other112
Unknown303
Not Reported202
08

Study locations

10 sites
  • St Jude Medical Center
    Fullerton, California 92835, United States
  • Medstar Heath Research Institute Medstar Washington Hospital Center
    Washington, District of Columbia 20010, United States
  • John D Archbold Memorial Hospital
    Thomasville, Georgia 31792, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • The Brigham and Womens Hospital, Inc
    Boston, Massachusetts 02115, United States
  • Rutgers University Hospital
    Newark, New Jersey 07103, United States
  • Therapeutics Concepts
    Houston, Texas 77004, United States
  • Joe Arrington Cancer Research and Treatment Center
    Lubbock, Texas 79410, United States
  • Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2020 to primary completion in Feb 2021, 6 months.

Results were first posted in Mar 2022, 1 year 1 month after primary completion.

Of 224 industry-sponsored phase 2 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 13. This study's 6 months is below that.

Counting every sponsor, half of 583 studies reached it within 9 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2020
First posted
May 11, 2020
StartActual
Jul 6, 2020
Primary completionActual
Feb 1, 2021
CompletionActual
Feb 1, 2021
Results first posted
Mar 2, 2022
Last update
Oct 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04382586
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
May 11, 2020
Start date
Jul 6, 2020
Primary completion
Feb 1, 2021
Completion
Feb 1, 2021
Results posted
Mar 2, 2022
Last update
Oct 26, 2024

Study contacts

Study Director
principal investigator · BeiGene

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zanubrutinib

Start the discussion